Sensitive tests designed to detect very small numbers of remaining leukemia cells after treatment, known as measurable residual disease (MRD), may provide an early and reliable indicator of long-term ...

Parexel, a leading global clinical research organization (CRO) providing insights-driven Clinical and Consulting solutions to the world’s life sciences industry, today announced the company has been ...

An early study of BGB-16673 for hard-to-treat leukemia found that side effects were manageable with no new safety concerns, per Dr. Lydia Scarfò. Patients with a subtype of lymphoma may be able to ...

TORONTO, July 3, 2025 /CNW/ - Vertex Pharmaceuticals (VRTX) (Nasdaq: VRTX) recently announced positive longer-term data for Pr CASGEVY ® (exagamglogene autotemcel) from global ongoing pivotal clinical ...

I’m writing from the heart of the EHA2025 Congress, hosted by the European Hematology Association (EHA), in Milan, Italy. I’m surrounded by leading experts, researchers, and, most importantly, fellow ...

MILAN — An unexpected highlight here at this year’s European Hematology Association (EHA) Congress came from beyond planet Earth. In a packed session titled Space Hematology, researchers and ...

LAUSANNE, Switzerland, June 12, 2025 /PRNewswire/ -- ADC Therapeutics SA (ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced updated ...